44 results about "Drug taking" patented technology

The invention relates to a heart rehabilitation management method based on rehabilitation requirements. The method comprises the following steps: acquiring oxygen saturation time sequence data of a patient through wearable equipment, performing biological rhythm feature extraction on the data to construct a fluctuation model so as to capture a physiological cycle rule, and constructing a drug action factor based on a drug taking record to perform drug action calibration on original data so as to eliminate exogenous interference. Candidate time windows with consistent physiological statuses are screened through sliding window stability analysis; dynamic baseline calculation is performed on the candidate window based on long-term monitoring data to establish an individualized reference standard, when the dynamic baseline reaches the standard, the biological rhythm parameters and the drug action factors are fused to score and screen the time window, and finally, an individualized rehabilitation training scheme is generated in combination with physiological feature matching of a patient. Dynamic synergy of drug metabolism, physiological rhythm and historical baselines is achieved, the problem of physiological load imbalance caused by a static training plan is solved, and the rehabilitation efficiency is improved while the heart compensation risk is remarkably reduced.

The invention discloses a mobile terminal lightweight drug taking auxiliary detection method and system based on a face image, and the method comprises the following steps: S1, collecting a face image of a detected person through a camera, and carrying out the preprocessing operation of face detection, background removal and face alignment; s2, designing a lightweight neural network module, and constructing a lightweight drug taking detection network based on the module; s3, acquiring a face data set of a drug addict and training a drug addict detection network; s4, extracting face features by using the drug taking detection network and obtaining a classification result and a certainty degree; and S5, converting and transplanting the drug taking detection network model to a mobile terminal, and constructing a mobile terminal application. According to the method, the drug addicts are detected based on the facial images, the defects that a traditional biochemical sample detection method is high in matching requirement, long in detection period, difficult to screen in a large range and the like are overcome, meanwhile, deep learning and lightweight thoughts are used, the algorithm performance is effectively improved, and the method is suitable for mobile terminal application scenes, portable application scenes and other application scenes.

The invention belongs to the technical field of medical management, and discloses an anesthetic medicine taking and supplementing comprehensive collaborative management system and method.The anesthetic medicine taking and supplementing comprehensive collaborative management system comprises a safe storage monitoring unit used for deploying a deformable magnetofluid sealing mechanism on an anesthetic medicine box, controlling the magnetofluid shape change through an electromagnetic signal, and sending the deformable magnetofluid sealing mechanism to the anesthetic medicine box when an unauthorized box opening behavior is monitored; the topological structure is triggered to deform to automatically lock the medicine box; the medicine taking operation unit is used for providing medicine taking path guidance through an AR interface of the medicine box and instructing the target medicine storage bin to take medicine in combination with the multi-band LED array; the medicine data insight unit is used for collecting the hemp essence medicine consumption data and the hemp essence medicine doctor advice data from the information storage terminal of the medicine storage bin, and constructing a hemp essence medicine consumption map through the hemp essence medicine consumption data; all-around safety protection, intelligent operation and accurate analysis and optimization are realized in the medicine management process, and the management efficiency, accuracy, safety and intelligent level of the hemp essence medicine are greatly improved.

The invention relates to the technical field of biological medicines, in particular to application of hsacirc0008126 in prevention and treatment of senile osteoporosis. The invention provides the circular RNA hsacirc0008126 which can be used for regulating and controlling the mesenchymal stem cell osteogenesis and adipogenic differentiation, the mechanism of the circular RNA hsacirc0008126 on the mesenchymal stem cell osteogenesis and adipogenic differentiation is different from that of the prior art, the medicine taking the circular RNA hsacirc0008126 as the target spot can be used for treating and / or preventing osteoporosis, and the circular RNA hsacirc0008126 has important application value.

The application discloses application of a reagent for detecting LRRN3 expression level in preparation of a benign prostatic hyperplasia diagnosis product. It is proved through cell function experiments and animal experiments that overexpression of the LRRN3 gene can inhibit the proliferation of prostate cells, block the cell cycle and promote cell apoptosis, thereby effectively inhibiting the prostatic hyperplasia. The discovery provides a new target and treatment strategy for the treatment of the prostatic hyperplasia, and provides a brand-new thought and method for the treatment of the prostatic hyperplasia. Based on the research results, a gene therapy drug taking the LRRN3 gene as a target can be further developed, for example, a lentivirus vector carrying the LRRN3 gene or other gene delivery systems are constructed and used for the treatment of the prostatic hyperplasia. In addition, the LRRN3 gene can be combined with other treatment methods to improve the treatment effect.

The invention discloses a medicine smashing device, and belongs to the technical field of medicine smashing. Comprising a crushing storage cavity used for crushing stored particles, a crushing device used for crushing particle medicines, a driving device used for driving the crushing device to operate, a capsule medicine storage cavity used for storing capsule medicines for taking, and a stirring and mixing device used for carrying out mixing operation on the interior of the capsule storage cavity. The transmission device is used for driving the stirring and mixing device in a transmission manner; the capsule separating device is used for separating capsules; according to the device, granular medicine can be crushed, so that a patient with dysphagia or a patient with digestive absorption capacity can take the medicine conveniently, the medicine can be better received and absorbed to be effectively treated conveniently, meanwhile, capsule medicine can be separated and then mixed with warm water to be taken, and the medicine taking efficiency is improved. And the capsule can be taken without being separated and mixed with warm water, so that the medicine taking of patients with dysphagia or digestive absorption capability is effectively improved.

The invention discloses an equipment fault diagnosis method based on big data analysis, and relates to the technical field of drinking or drug taking detection, and the method comprises the following steps: S101, collecting the operation state information, including sensor response information and sensor resistance information, of a skin resistance sensor in a driving state rapid detection system, and after collection, sending the information to a database; and processing sensor response information and sensor resistance information when the skin resistance sensor operates. The running state of the skin resistance sensor in the driving state rapid detection system is monitored, abnormal hidden dangers of the running state of the skin resistance sensor are effectively prevented, and therefore the situation that the accuracy and reliability of the system are affected due to the fact that the skin resistance sensor generates wrong measurement results is effectively prevented; therefore, the system cannot reliably detect drunk driving and toxic driving behaviors, and cannot provide accurate alarms or trigger corresponding safety measures.

The invention relates to the technical field of medication data processing, in particular to a medication reminding system and method for the elderly, and the system comprises a medicine dependence analysis module which extracts medicine dependence information based on collected daily medication data of the elderly, builds a directed graph model of medicine taking, and carries out the medicine taking of the elderly in the directed graph model of medicine taking, the nodes represent medicines to be taken, and the edges represent dependency information among the medicines. According to the method, the time, the interval and the interaction information among the medicines in the medication data of the old people are extracted, and the relevance among the medicines is displayed in a quantitative mode. The reminding time is optimized according to the dependency relationship of the medicines, the coordination effect of the positive correlation medicines is enhanced, and the potential conflicts of the negative correlation medicines are reduced. Based on the reminding response data of the user, the reminding frequency and the distribution sequence are dynamically adjusted, interference of multiple times of abnormal reminding on the user is reduced, and the actual execution effect of system reminding is further improved.

The invention provides a medical drug intelligent rental cabinet system integrating identity verification and drug use safety early warning, and relates to the technical field of water turbine blade detection, and the system comprises an identity verification module which is used for carrying out the identity information collection and validity verification of a drug taking person; the medication information matching module is used for matching the identity information of the personnel passing the identity verification with pre-stored medication prescription information; the drug use safety early warning module is used for analyzing the drug use risk based on the matching result and generating early warning information; dependence of traditional manual registration and verification is thoroughly eliminated, non-sensitization and high efficiency of identity verification and precision of medicine matching are achieved, adaptation limitation of single-mode verification is avoided, manual judgment errors are eradicated through automatic data retrieval, it is ensured that each time of medicine taking corresponds to legal personnel and compliant prescriptions, and the accuracy of medicine taking is improved. And a safety defense line for medicine access is built from the source.

The invention discloses a reversible multi-nozzle needleless injection ampoule with a turbulent flow mixing function, and belongs to the technical field of medical instruments. Due to the design of the integrally-formed nozzle base, all dynamic sealing interfaces which may fail under high pressure are eliminated, so that the pressure resistance of the ampoule is greatly improved, and the service life of the ampoule is greatly prolonged; according to intelligent switching of the injection modes, a user can switch between the deep precise injection mode and the superficial broad-spectrum coverage mode through simple rotating operation, unprecedented clinical adaptability is given to the ampoule, clear tactile / auditory feedback is achieved in the switching process, the clinical adaptability is high, and operation is convenient and fast. The multifunctional injector integrates the functions of injection mode switching, liquid medicine mixing and front-end medicine taking, and the clinical adaptability and operation convenience are improved.

The application relates to application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, and belongs to the technical field of biological medicine. In order to solve the problem that effective clinical means for treating vascular calcification is lacked at present, the application provides application of a medicine taking ACLY gene as an action target in preparation of a medicine for preventing and treating vascular calcification, the transcription or translation of the ACLY gene of vascular smooth muscle cells is efficiently and specifically inhibited, or the expression or activity of the ACLY protein of the vascular smooth muscle cells is efficiently and specifically reduced, the osteogenic differentiation of smooth muscle is reduced, the deposition of hydroxyapatite in the vascular media is reduced, and the progress of vascular calcification is alleviated. The medicine for preventing and treating vascular calcification is prepared on the basis of inhibition of the ACLY of vascular smooth muscle, has important clinical application potential for vascular calcification treatment, and can provide a new treatment option for patients with vascular calcification.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a 4-aminopyridine sustained release preparation and a preparation method thereof. The sustained release preparation comprises 4-aminopyridine, ethyl-beta cyclodextrin-calcium carbonate microspheres, a filler, an adhesive, a disintegrating agent and a lubricant. According to the sustained-release preparation, the sustained-release time can be prolonged, the medicine taking frequency is reduced, the content uniformity of the preparation is improved, meanwhile, the preparation process is improved, and stimulation to operators, environment control in a production workshop and equipment cost are reduced.

The present application relates to the field of biological medicine, in particular to the preparation of a drug or diagnostic reagent for treating Philadelphia chromosome positive leukemia by taking synaptic receptor associated protein RAPSYN or its gene as a target point. The present application specifically discloses the use of RAPSYN gene or protein as a therapeutic target in screening and / or preparation of a drug for preventing and / or treating Philadelphia chromosome positive leukemia. Philadelphia chromosome positive leukemia can be treated by negatively regulating the level and activity of RAPSYN gene or protein. The efficacy and prognosis of patients can be predicted by detecting the expression level of RAPSYN. The treatment strategy or drug taking RAPSYN gene and protein as a target point can be used as a new means of leukemia targeted therapy.

The invention relates to the technical field of medical instruments, in particular to a sepsis patient antibiotic use timer, which comprises a timing drug delivery system, a timer and a drug taking device, and is characterized in that the timing drug delivery system comprises a receiving module, a grouping timing module, a severe case monitoring module, a drug delivery module and a data recording module; the grouping timing module is used for grouping according to the information of the timer and calculating definite diagnosis or suspected definite diagnosis time, and the drug administration module is used for analyzing the types of germs of patients diagnosed with sepsis and generating corresponding drug administration time and drug administration amount data of antibiotics. The intensive care monitoring module is used for monitoring the antibiotic use condition of the patient in real time under the intensive care condition. Through cooperation of the administration module and the severe case monitoring module, an antibiotic administration scheme is adjusted in real time according to the condition of a patient so as to provide reference for medical staff, and the timeliness and effectiveness of treatment are improved.

The present invention discloses a method and system for managing cardiovascular and cerebrovascular disease information, which relates to the field of disease information management. The present invention obtains the disease severity level data of patients with cardiovascular and cerebrovascular diseases to be managed by constructing a final mapping equation for the severity level of cardiovascular and cerebrovascular diseases, and determines whether the patients with cardiovascular and cerebrovascular diseases to be managed need to take medicine; then, by comparing the disease severity data obtained from the aspect of drug taking of the patients with cardiovascular and cerebrovascular diseases to be managed with the disease severity data obtained from the aspect of the patients' disease information data, it is determined whether the current drug taking of the patients with cardiovascular and cerebrovascular diseases to be managed is reasonable, so as to make timely adjustments, which is beneficial to the recovery of the patients' conditions; among them, by setting the error threshold of the severity level mapping data, a quantitative judgment basis is provided for determining whether the mapping accuracy of the initial mapping equation for the severity level of cardiovascular and cerebrovascular diseases meets the requirements.

The invention relates to a medicine taking device, a medicine storage device and a medicine taking system. The medicine taking device comprises a base unit, a main body unit, a first ejection unit, a plurality of opening and closing units, a sealing unit, a second ejection unit, a third ejection unit, a taking-out unit and a control unit. The medicine storage device has the advantages that the base unit, the main body unit and the first ejection unit are used in cooperation, and the medicine storage device can be classified and stored in order; the opening and closing unit, the control unit and the prompting unit are matched for use, so that the time for taking medicine can be preset, the corresponding discharging opening is opened at the specific time, old people are reminded to take medicine on time, the problems of missing taking and wrong taking caused by memory deterioration are solved, and it is ensured that the old people can accurately take out the needed medicine every time; and the medicine storage device can be moved out of the main body unit through the second ejection unit, so that the medicine storage device can be conveniently cleaned and arranged, and medicine management is more efficient and convenient.

The invention provides a rapid drug taking screening method and device.The rapid drug taking screening method comprises the steps that skin spectral characteristics of a to-be-recognized user are obtained, and the skin spectral characteristics comprise at least one of skin structure characteristics, skin fingerprint characteristics and skin component characteristics; wherein the skin structure characteristics refer to the characteristics of macromolecular structures of the skin, the skin fingerprint characteristics refer to the characteristics of residual traces of foreign molecules on the skin, and the skin component characteristics refer to the characteristics of the content of inherent components on the skin; acquiring trace element characteristics of the user to be identified, wherein the trace element characteristics comprise at least one of the following characteristics: a zinc element concentration characteristic, an iron element concentration characteristic and a copper element concentration characteristic; and carrying out fusion analysis on the skin spectral features and the trace element features, and judging whether the to-be-identified user has a drug taking behavior or not based on a preset identification model. According to the embodiment of the invention, the screening accuracy and screening efficiency of the drug taking behavior can be effectively improved.

The present invention provides an anesthesia dispensing robot, which relates to the field of robot technology and includes: a drug storage area, a drug taking component, a drug review component, a drug preparation component, a display component, an input component, and a processor arranged in the robot's main structure; the drug storage area includes multiple storage partitions, each storage partition is used to store a type of anesthetic drug; the drug taking component is used to take anesthetic drugs from the drug storage area according to the drug taking instruction of the processor; the drug review component is used to weigh the amount of anesthetic drugs taken; the drug preparation component is used to mix the taken anesthetic drugs and produce anesthetic medical devices when the amount of anesthetic drugs taken is consistent with the drug taking instruction, and the processor is used to generate the drug taking instruction. According to the present invention, based on the doctor's modification and confirmation of the recommended anesthetic drug dispensing information, the recommended anesthetic drug dispensing information can be optimized to improve the accuracy of the recommendation.

The invention provides an anesthesia dispensing robot, which relates to the technical field of robots and comprises a medicine storage area, a medicine taking assembly, a medicine rechecking assembly, a medicine blending assembly, a display assembly, an input assembly and a processor which are arranged in a robot main body structure, the medicine storage area comprises a plurality of storage subareas, and each storage subarea is used for storing one type of anesthetic medicine; the medicine taking assembly is used for taking anesthetic from the medicine storage area according to a medicine taking instruction of the processor; the medicine rechecking assembly is used for weighing the dosage of the anesthetic medicine; the medicine blending assembly is used for mixing the taken anesthetic medicines and manufacturing anesthetic medicine medical equipment under the condition that the taking amount of the anesthetic medicines is consistent with the medicine taking instruction, and the processor is used for generating the medicine taking instruction. According to the method and the device, the recommended anesthetic medicine dispensing information can be optimized based on modification and confirmation of the recommended anesthetic medicine dispensing information by a doctor, and the recommendation accuracy is improved.

The utility model relates to the technical field of protective masks, in particular to a chemical safety protective mask which comprises a mask and a storage box, the side face of the mask is fixedly connected with a hose used for transmission, one end of the hose is fixedly connected with an air pump, and the upper end of the air pump is fixedly connected with a protective shell used for protection. The inner wall of the protective shell is fixedly connected with a smoke filtering layer used for filtering, and the lower end of the smoke filtering layer is connected with a drug taking layer used for filtering in a clamped mode. According to the chemical safety protection mask, through cooperative arrangement of an air pump, a protection shell and a smoke filtering layer, when a worker uses the mask, the flowing speed of air in the mask can be increased, meanwhile, air outside equipment is sucked into an air inlet pipe by means of suction force generated by the air pump, air filtering of the smoke filtering layer and a drug taking layer is accelerated, and the safety of the worker is improved. And the problem that when air enters the mask, filtering is slow, and therefore it is difficult for workers to breathe is solved.

The application discloses a controlled-release pharmaceutical composition and a preparation method and application thereof. The controlled-release pharmaceutical composition comprises a quick-release part and an enteric sustained-release part; the quick-release part comprises a first active ingredient, and the enteric sustained-release part comprises a second active ingredient and a sustained-release material; the first active ingredient or the second active ingredient is selected from racemic indobufen or S-indobufen or a pharmaceutically acceptable salt thereof; and the sustained-release material is selected from one or a combination of any number of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, xanthan gum, sodium alginate, sodium carboxymethyl cellulose, acrylic resin, carbomer or polyethylene oxide. The composition can realize once-a-day oral administration, reduces the frequency of drug taking of a patient, and improves the drug taking compliance of the patient; the preparation process is simple, short in time, low in energy consumption, and suitable for industrial production; the influence of food on product burst release is greatly reduced, the stimulation and adverse reactions of the product on the gastrointestinal tract are reduced, and in particular, the risk of gastric hemorrhage is reduced.

The present application relates to a kind of sustained-release acyclovir tablets and its preparation process, belong to the technical field of medicine.The acyclovir tablet provided by the present application has immediate-release layer and sustained-release layer, immediate-release layer can be quickly released, rapidly increase the blood concentration in human body;Sustained-release layer has multi-stage drug release characteristics, it includes three kinds of sustained-release particles, which can effectively delay, positioning release drug, constantly supplement the blood concentration in body, maintain stable blood concentration, can effectively sustain release up to about 12h, and can maintain relatively stable blood concentration within 12 hours, reduce the frequency of drug taking, improve patient compliance, suitable for the patient with herpes simplex virus infection who needs long-term treatment.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The invention discloses a crime factor correlation analysis method considering spatial heterogeneity and a zero dilatation phenomenon, which comprises the following steps of: firstly, acquiring spatio-temporal data and social population data of drug taking and drug selling cases, and obtaining initial environment factors to carry out collinearity diagnosis, screening and standardization processing to obtain built environment factors; analyzing the spatial distribution similarity of drug taking and drug selling cases; dividing analysis units, and constructing a zero-expansion negative binomial model of each analysis unit by taking the quantity of drug taking and drug selling cases as modeling objects; iterative alternative optimization is carried out on the model coefficients, and the incidence rate and the advantage ratio of explanatory variables between each built-up environment factor and the social population data are calculated; then, the optimized model is adopted to estimate regression coefficients of built environmental factors, a kernel density distribution diagram is generated, and a hotspot distribution diagram of drug taking and drug selling cases is visualized; finally, a targeted urban environment intervention strategy is provided according to a model result, and a scientific basis is provided for urban safety planning and police resource allocation and prevention.

The invention discloses a nilotinib sustained release tablet and a preparation method thereof, the nilotinib sustained release tablet comprises a bleaching assisting layer and a drug-containing sustained release layer, the bleaching assisting layer is prepared from a hydrophilic polymer with the viscosity of 2000 mpa.s-6000 mpa.s, a hydrophobic bleaching assisting agent, an adhesive and a lubricant; the drug-containing sustained-release layer is prepared from the following raw materials: an amorphous solid dispersion containing nilotinib or salt thereof, a hydrophilic polymer with the viscosity of 40 mpa.s-2000 mpa.s, a water-soluble filler, a flow aid and a lubricant. The nilotinib sustained-release tablet can effectively prolong the retention time of nilotinib in the stomach, slowly release the medicine in the stomach, improve the solubility and bioavailability of the medicine and reduce the overall dosage, so that the adverse reaction of the medicine is reduced, and meanwhile, on the basis of ensuring that the nilotinib sustained-release tablet is not affected by food effects, the nilotinib sustained-release tablet only needs to be orally taken once every day, and the curative effect of the nilotinib sustained-release tablet is greatly improved. The medicine taking compliance of a patient is improved by reducing the medicine taking times.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The invention discloses an application of a Prmt5 gene and a substance for regulating expression of the Prmt5 gene in preparation of a product for treating cerebellar ataxia. The invention belongs to the technical field of biology, and particularly relates to an application of a Prmt5 gene and a substance for regulating expression of the Prmt5 gene in preparation of a product for treating cerebellar ataxia. The invention provides an application of a drug taking a Prmt5 gene as a drug action target in preparation of a drug for treating or preventing cerebellar ataxia related diseases and an application of a product for reducing formation of inhibitory synapses.

The application discloses a metabolically stable anti-drug-resistant main protease inhibitor and application thereof in preparation of antiviral drugs. In the main protease inhibitor, the group C can be effectively combined with the active pocket of the main protease, and the combination mainly depends on the 163th amino acid site of the main protease; meanwhile, the group C is difficult to be oxidized, so that the main protease inhibitor can exhibit basically consistent inhibitory activity to both mutant strains and wild strains, the virus cannot produce drug resistance to the main protease inhibitor of the application, and the main protease inhibitor has excellent anti-drug resistance activity and metabolic stability, and does not need to be used in combination with a liver enzyme inhibitor when used, which is favorable for reducing self-liver function reduction and toxic side effects caused by drug taking. In addition, the group A can further improve the inhibitory activity of the main protease inhibitor to the main protease, and can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the B ring mainly plays a role in further improving the inhibitory activity of the main protease inhibitor to the main protease.

The invention discloses a preparation method of a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, and relates to the technical field of medicines, the pharmaceutical composition comprises a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong injection as a Xiaoshuitong According to the preparation method of the pharmaceutical composition for treating the cardiovascular and cerebrovascular diseases, multi-target and multi-layer treatment is realized by comprehensively applying six methods of traditional Chinese medicine, and the cardiovascular and cerebrovascular functions are conditioned fundamentally; the medicine composition has a strong synergistic effect, and can be used for dissolving thrombus and dredging collaterals, repairing vascular endothelium and promoting myocardial cell regeneration; the treatment mode is safe, and western medicine operation wounds and side effects caused by long-term medicine taking are avoided; oral administration and intravenous administration are combined, so that the drug absorption and action persistence are enhanced; the traditional Chinese medicine external treatment method can be matched to further improve the curative effect and realize metabolic balance.

The present invention relates to the field of drug delivery technology, and proposes a drug delivery device and method for a pharmacy, which can realize drug delivery while having good independence of the drug delivery channel, and is independent of the external space during the drug delivery process, can reduce the conduction of bacteria during the drug delivery process, is more flexible in installation and placement, is more convenient for adjusting the delivery path, is more convenient to use, and has better practicality. It includes a drug taking mechanism, a drug releasing mechanism and a drug transport carrier, the drug taking mechanism and the drug releasing mechanism both include top opening parts, the two top opening parts are connected through a fine-tuning tube, and multiple electromagnets are installed outside the fine-tuning tube and the two top opening parts, the drug transport carrier includes two mobile frames, multiple external support wheel groups are installed outside the two mobile frames, the multiple external support wheel groups are matched with the fine-tuning tube and the two top opening parts, the two mobile frames are fixedly connected with iron columns, the two iron columns are matched with electromagnets, and the ends of the two mobile frames close to each other are fixedly connected with connecting springs.